Stacey Seltzer - Partner, Aisling Capital
Strategies and subsectors driving strong PE returns in Healthcare: risks and opportunities for LPs. So what drives the outperformance? What are the risks and opportunities for LPs going forward?
IIR & IBC Finance is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Partner at Aisling Capital
Ms. Seltzer joined Aisling in 2008 and currently serves as a Partner. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia for five years. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.
Ms. Seltzer serves as a director of Aimmune Therapeutics and Miramar Labs. Previously, she served as a Board observer for Agile Therapeutics, Durata Therapeutics and ZELTIQ Aesthetics. She also acted as the Aisling representative for its investment in Precision Dermatology and was closely involved in Aisling’s investments in Cytos, Dermira and PowerVision.